arrow
T

Tetsuhiko Asao

Juntendo University
H指数:21
被引数:1,468

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development of a multimodal fully automated ensemble model to predict EGFR mutation and efficacy of EGFR-TKI in non-small cell lung cancer

开发一种多模态全自动集成模型以预测非小细胞肺癌中EGFR突变和EGFR-TKI疗效

2025-12-310
PRE
Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial

度鲁妥单抗、卡铂和依托泊苷用于治疗初治广泛期小细胞肺癌且体力状况较差的患者(NEJ045A):一项单臂Ⅱ期试验

2025-09-280
PRE
Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2

肺促血栓形成微环境中的外泌体通过整合素β2驱动肿瘤相关血栓形成和转移

CELL
IF42.5
2025-02-012
PRE
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older
2024-06-173
OAAI
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)
2024-04-133
OAAI
Usefulness of Computed Tomography for Evaluating the Effects of Bronchial Thermoplasty in Japanese Patients with Severe Asthma

计算机断层扫描对评估日本严重哮喘患者支气管热成形术效果的有用性

2024-04-010
OAAI
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study)
2024-01-021
OAAI
Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101)
2023-11-012
PRE
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
2023-03-063
OAAI
A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol

卡铂和依托泊苷联合durvalumab治疗先前未经治疗的表现状态不佳 (PS) 的广泛期小细胞肺癌 (ES-SCLC) 患者的II期研究: NEJ045A研究方案

2022-11-045
OAAI
Safety of immune checkpoint blockade in lung cancer and pre-existing autoimmune diseases: NEJ047 multi-center study
2022-07-010
OAAI